



Neurotech forms Scientific Advisory Board

Perth, Australia & Malta – 20 December 2016 – Developer of quality medical solutions in the neuroscience space, Neurotech International Limited (ASX: NTI), has finalised the appointment of its Scientific Advisory Board (SAB).

The SAB will act as strategic counsel to Neurotech, guiding company management as it enters the market with its Mente Autism device, in addition to the development of other devices targeting various neurological disorders.

The SAB is comprised of:

- **Prof Paolo Cavallari – Professor of Human Physiology, University of Milan**
- **Prof Denis Azzopardi – Professor of Neonatal Medicine, Kings College, UK**
- **Dr David S Cantor – Former President of the EEG and Clinical Neuroscience Society, USA**
- **Dr Anton Grech – Senior Research Fellow, Bedfordshire Centre for Mental Health Research**

Full biographies for each member of the SAB are available below.

Neurotech's Founder and Chief Scientific Officer Dr Adrian Attard Trevisan will act as moderator/chair to the SAB, with Dr Marco Rotonda, the company's Senior Neuroscientist, filling the role of board secretary.

"As a company we are very excited to have the input of such a high calibre group of individuals in the neuroscience space," said Dr Attard Trevisan.

"To attract such talent onto our Scientific Advisory Board is excellent validation of Neurotech, its technology and direction."

The SAB will convene once per quarter with each member requiring re-election every calendar year. Additional members may be added in the future, with a view to having exposure within other geographies.

The key deliverable expected of the SAB is a 'Company Vision Document', which will be delivered to the Board of Neurotech in the final quarter of each calendar year.

"We have assembled a team for our Scientific Advisory Board with wide-ranging, high quality experience relevant to Neurotech's business activities and objectives, and reflective of the jurisdictions the company is targeting in the immediate to medium term," Neurotech's CEO Wolfgang Storf said.

"The aim and functions of the Scientific Advisory Board are extremely important to Neurotech, and we expect it will act as a key decision maker for the company's scientific and technological vision."

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

Biographies

Prof Paolo Cavallari, MD PhD

Paolo Cavallari is Professor of Human Physiology (2001) at the Medical School of the Università degli Studi in Milan, Italy. Prof Cavallari received his MD (magna cum laude) from the University of Milan in 1982, a Diplome d'Etudes Appofondies in Neurophysiology from the Pierre et Marie Curie University of Paris in 1984, a Doctorat de l'Université from the same university in 1988 and a PhD in Neurological Science from the University of Milan in 1990. He received fellowships from the European Neuroscience Association (1984) and from the IBRO-Wenner-Gren Foundation (1986). He had non-tenure track positions from the INSERM (France, 1985) and the Göteborg University (Sweden, 1987), and tenured as Associate Professor of Human Physiology in 1992 at the Università degli Studi of L'Aquila (1992-1997), and at Università degli Studi (1997-2001).

Prof Denis Azzopardi, MD PhD

Denis Azzopardi is Professor of Neonatal Medicine at Kings College, London. For many years he has been involved in clinical research in the investigation, assessment and treatment of neonatal encephalopathy, having developed and implemented the first proven therapy to reduce severe brain damage and improve survival after birth asphyxia. In developing this therapy, magnetic resonance spectroscopy was used to demonstrate birth asphyxia in newborn infants leads to delayed brain injury, and that there is a 'lucid period' when neuroprotective treatments could potentially be applied. This in turn led to the now standard practice of cooling infants below normal body temperature as the standard practice for those suffering from oxygen deprivation during birth in the United Kingdom (UK). Estimates suggest that this treatment has saved the UK over £100 million in the costs of caring for people affected by birth asphyxia, and is now implemented across the world.

Dr David S Cantor, PhD

Dr David Cantor received his Bachelor's Degree with Distinction in Psychology from the University of Connecticut. His honours work was in the field of neurophysiological correlates of cross modal integration processes in attention deficit disorders. He received his Masters and Doctorate in psychology at the State University of New York (Stony Brook), where his thesis was focussed on quantitative EEG correlates of autism. He most recently received his Postdoctoral Masters of Science in Psychopharmacology from Fairleigh University.

Dr Cantor is a Fellow with the American College of Forensic Examiners, National Academy of Neuropsychology, and the Academy of Learning and Developmental Disorders. He is also Former President of the EEG and Clinical Neuroscience Society and has also been accepted for special fellowships including Congressional Fellow of the American Psychological Association and the State of New York Intercampus Fellow in the area of brain research.

Dr Anton Grech, MD PhD

Dr Anton Grech graduated as Doctor of Medicine from the University of Malta in 1992. He became a Member of the Royal College of Psychiatrists, UK, in 1997 and a Fellow of the same college in 2011. In 1999 he obtained an M.Sc. in Psychiatry from King's College, University of London. He trained and worked at the Maudsley Hospital in London, between 1994 and 1998. During 1998 he was also a Clinical-Academic Lecturer in the Department of Psychiatry, Institute of Psychiatry, King's College, University of London.

Dr Grech returned to Malta in 1999, where he was Senior Registrar in Psychiatry with the National Health Service of Malta until 2003, when he was appointed Consultant Psychiatrist with a special interest in Addictions and Neuropsychiatry. In 2000 he was appointed Lecturer in the Department of Psychiatry of the Faculty of Medicine and Surgery at the University of Malta, and in 2008 he was appointed as Senior Lecturer within the same department. In 2011 he was appointed as Senior

Research Fellow in the Bedfordshire Centre for Mental Health Research in association with the University of Cambridge, United Kingdom. In 2011 he was also appointed as Clinical Chairman of the Department of Psychiatry in the Ministry of Health, Malta.

Dr Grech's work has been published in international psychiatric journals, and he has presented and chaired in various international psychiatric conferences. In 2008 he was chosen as one of the 30 European Scientists to be featured in the book 'Portraits of Science; Scientists of Tomorrow', published by the European Federation of Pharmaceutical Industries and Associations, to commemorate its 30th anniversary.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.
<http://www.mentetech.com>.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: <http://www.neurotechinternational.com>.

For more information please contact:

Matthew Wright
matt@nwrcommunications.com.au
Tel: +61 451 896 420